Heterogeneity of Treatment Effect for Intra-Aortic Balloon Pump Use Across Lactate Trajectories in Cardiogenic Shock Patients Supported by VA-ECMO: An Analysis of the Chinese Extracorporeal Life Support Registry

Abstract

This study aimed to investigate the heterogeneity of treatment effect for intra-aortic balloon pump (IABP) across various lactate trajectories in patients with acute myocardial infarction-related cardiogenic shock (AMICS) supported by veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Retrospective data from the China Extracorporeal Life Support Registry included AMICS patients who received VA-ECMO. The latent class growth model was used to identify distinct lactate trajectories. The primary outcome was in-hospital mortality. Baseline characteristics and outcomes were compared across trajectory classes, and the heterogeneity of treatment effect for IABP was assessed. Among 1264 patients, three lactate trajectories were identified. Compared with Class 1, both Class 2 (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.54–2.67) and Class 3 (OR 3.99, 95% CI 2.77–5.78) had significantly higher in-hospital mortality. Moreover, heterogeneity of treatment effect across the classes was found. IABP use was associated with increased risks of in-hospital mortality and multiple complications (bleeding, renal, metabolic, and infection) in Class 1, whereas no associations were observed in Class 2 or Class 3, except for a higher risk of infection in Class 2. In summary, lactate trajectories can stratify mortality risk in AMICS patients receiving VA-ECMO support and reflect heterogeneous responses to IABP treatment.

Keywords

cardiogenic shock / heterogeneity of treatment effect / intra-aortic balloon pump / lactate trajectory / myocardial infarction / veno-arterial extracorporeal membrane oxygenation

References

[1] R. J. Goldberg, J. M. Gore, J. S. Alpert, et al., “Cardiogenic Shock After Acute Myocardial Infarction: Incidence and Mortality From a Community-wide Perspective, 1975 to 1988,” New England Journal of Medicine 325, no. 16 (1991): 1117–1122.

[2] A. Babaev, P. D. Frederick, D. J. Pasta, et al., “Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock,” JAMA 294, no. 4 (2005): 448–454.

[3] B. Kidd, K. Hughes, T. Zorn, et al., “Outcomes of Patients Requiring VA-ECMO for Cardiogenic Shock and Evaluation of Programmatic Changes,” Journal of Cardiothoracic and Vascular Anesthesia 39, no. 8 (2025): 2095–2101.

[4] C. H. Wang, Y. S. Chen, and M. H. M. Ma, “Extracorporeal Life Support,” Current Opinion in Critical Care 19, no. 3 (2013): 202–207.

[5] Y. S. Chen, H. Y. Yu, S. C. Huang, et al., “Extracorporeal Membrane Oxygenation Support Can Extend the Duration of Cardiopulmonary Resuscitation,” Critical Care Medicine 36, no. 9 (2008): 2529–2535.

[6] P. Ostadal, R. Rokyta, J. Karasek, et al., “Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial,” Circulation 147, no. 6 (2023): 454–464.

[7] I. Yeo, R. Axman, D. Y. Lu, et al., “Impella Versus Intra-Aortic Balloon Pump in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: An Observational Study,” Journal of the American Heart Association 13, no. 3 (2024): e032607.

[8] H. Thiele, U. Zeymer, F. J. Neumann, et al., “Intraaortic Balloon Support for Myocardial Infarction With Cardiogenic Shock,” New England Journal of Medicine 367, no. 14 (2012): 1287–1296.

[9] L. S. Wang, X. Hao, C. L. Li, et al., “Intra-Aortic Balloon Pump in Patients Undergoing VA-ECMO: An Analysis of the Chinese Extracorporeal Life Support Registry,” Critical Care 28, no. 1 (2024): 93–95.

[10] K. X. Wang, L. S. Wang, J. W. Ma, et al., “Intra-Aortic Balloon Pump After VA-ECMO Reduces Mortality in Patients With Cardiogenic Shock: An Analysis of the Chinese Extracorporeal Life Support Registry,” Critical Care 28, no. 1 (2024): 394–404.

[11] T. K. S. Nishi, M. Ishii, K. Tsujita, et al., “Outcomes of Venoarterial Extracorporeal Membrane Oxygenation plus Intra-Aortic Balloon Pumping for Treatment of Acute Myocardial Infarction Complicated by Cardiogenic Shock,” Journal of the American Heart Association 11, no. 7 (2022): e023713.

[12] C. Baran, E. Ozcinar, A. Kayan, N. Dikmen, C. S. Baran, and M. B. Inan, “Comparison of ECMO, IABP and ECMO + IABP in the Postoperative Period in Patients With Postcardiotomy Shock,” Journal of Cardiovascular Development and Disease 11, no. 9 (2024): 283–293.

[13] P. Ponikowski, A. A. Voors, S. D. Anker, et al., “2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,” European Journal of Heart Failure 18, no. 8 (2016): 891–975.

[14] B. Ibanez, S. James, S. Agewall, et al., “2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation,” European Heart Journal 39, no. 2 (2018): 119–177.

[15] F. J. Neumann, M. Sousa-Uva, A. Ahlsson, et al., “2018 ESC/EACTS Guidelines on Myocardial Revascularization,” European Heart Journal 40, no. 2 (2019): 87–165.

[16] J. Hernandez-Montfort, S. S. Sinha, K. L. Thayer, et al., “Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock,” Circulation: Heart Failure 14, no. 5 (2021): e007924.

[17] M. Yuzefpolskaya, S. Schwartz, A. Ladanyi, et al., “The Role of Lactate Metabolism in Heart Failure and Cardiogenic Shock: Clinical Insights and Therapeutic Implications,” Journal of Cardiac Failure 32, no. 1 (2026): 115–125.

[18] T. Aksoy, A. H. Arslan, M. Ugur, and H. Ustunsoy, “Lactate and Lactate Clearance Are Predictive Factors for Mortality in Patients With Extracorporeal Membrane Oxygenation,” Brazilian Journal of Cardiovascular Surgery 39, no. 2 (2024): e20230091.

[19] M. Pagnesi, M. Riccardi, A. Sacco, et al., “Lactate Values and Mortality in Patients With Cardiogenic Shock: Insights From the Altshock-2 Registry,” Critical Care Medicine 53, no. 8 (2025): e1621–e1629.

[20] T. T. Lin, M. H. Lin, C. K. Wu, et al., “Early Lactate Changes Improve the Outcome Prediction for Extracorporeal Membrane Oxygenation,” European Journal of Cardio-Thoracic Surgery 58, no. 5 (2020): 915–922.

[21] P. Attanà, C. Lazzeri, M. Chiostri, G. F. Gensini, and S. Valente, “Dynamic Behavior of Lactate Values in Venous-Arterial Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest,” Resuscitation 84, no. 12 (2013): e145–e146.

[22] H. Y. Zhang, Z. P. Li, W. Q. Zheng, et al., “Risk Stratification of Patients With Acute Respiratory Distress Syndrome Complicated With Sepsis Using Lactate Trajectories,” BMC Pulmonary Medicine 22, no. 1 (2022): 339–349.

[23] Y. Wei, J. Q. Zhuang, J. Q. Li, et al., “Lactate Trajectories and Outcomes in Patients With Sepsis in the Intensive Care Unit: Group-Based Trajectory Modeling,” Frontiers in Public Health 13 (2025): 1610220.

[24] Y. X. Wang, G. M. Chen, M. Han, et al., “Early Lactate Trajectories Predict Mortality in Sepsis-Associated Acute Lung Injury: A Retrospective Cohort Study,” Respiratory Medicine 249 (2025): 108471.

[25] Z. R. Zhao, Y. Liu, and H. H. Ji, “Association Between Serum Lactate and Mortality in Critically Ill Ischemic Stroke Patients Based on MIMIC-IV Data,” Scientific Reports 15, no. 1 (2025): 26155.

[26] Z. H. Liang, M. Zhao, K. T. Liu, et al., “Lactate Trajectories in Early Survivors of Sepsis: A New Lens on Mortality Risk,” Shock 64, no. 4 (2025): 386–396.

[27] B. Levy, N. Girerd, G. Baudry, et al., “Serial Daily Lactate Levels Association With 30-Day Outcome in Cardiogenic Shock Patients Treated With VA-ECMO: A Post-Hoc Analysis of the HYPO-ECMO Study,” Annals of Intensive Care 14, no. 1 (2024): 43–54.

[28] J. A. Marbach, P. Di Santo, N. K. Kapur, et al., “Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial,” Journal of the American Heart Association 11, no. 6 (2022): e023322.

[29] A. G. Solomonean, M. I. Dregoesc, M. Istrate, et al., “Dynamic Arterial Lactate Values Are Associated With 30-Day Mortality in Patients With Acute Myocardial Infarction and Cardiogenic Shock on Intra-Aortic Balloon Pump Circulatory Support,” Cardiology 150, no. 6 (2025): 596–607.

[30] H. V. Barron, N. R. Every, L. S. Parsons, et al., “The Use of Intra-Aortic Balloon Counterpulsation in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 2,” American Heart Journal 141, no. 6 (2001): 933–939.

[31] P. T. O'Gara, F. G. Kushner, and D. D. Ascheim, “2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary,” Journal of the American College of Cardiology 61, no. 4 (2013): 485–510.

[32] E. M. Antman, D. T. Anbe, et al., “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation 110, no. 5 (2004): 588–636.

[33] H. Thiele, U. Zeymer, F. J. Neumann, et al., “Intra-Aortic Balloon Counterpulsation in Acute Myocardial Infarction Complicated by Cardiogenic Shock (IABP-SHOCK II): Final 12 Month Results of a Randomised, Open-Label Trial,” Lancet 382, no. 9905 (2013): 1638–1645.

[34] N. Morici, A. Sacco, S. Frea, et al., “Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock,” Journal of the American College of Cardiology 85, no. 16 (2025): 1587–1597.

[35] D. F. Fang, D. D. Yu, J. B. Xu, W. Ma, Y. X. Zhong, and H. B. Chen, “Effects of Intra-Aortic Balloon Pump on In-hospital Outcomes and 1-Year Mortality in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock,” BMC Cardiovascular Disorders 23, no. 1 (2023): 425–431.

[36] U. Zeymer, M. Hochadel, K. E. Hauptmann, et al., “Intra-Aortic Balloon Pump in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results of the ALKK-PCI Registry,” Clinical Research in Cardiology 102, no. 3 (2013): 223–227.

[37] F. Romeo, M. C. Acconcia, D. Sergi, et al., “The Outcome of Intra-Aortic Balloon Pump Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock According to the Type of Revascularization: A Comprehensive Meta-Analysis,” American Heart Journal 165, no. 5 (2013): 679–692.

[38] Z. L. Chen, Y. P. Gao, and Y. Y. Lin, “Perspectives and Considerations of IABP in the Era of ECMO for Cardiogenic Shock,” Advances in Therapy 40, no. 10 (2023): 4151–4165.

[39] M. A. Brown, F. H. Sheikh, S. Ahmed, S. S. Najjar, and E. J. Molina, “Intra-Aortic Balloon Pump as a Bridge to Durable Left Ventricular Assist Device,” Journal of the American Heart Association 10, no. 15 (2021): e019376.

[40] E. Von Elm, D. G. Altman, M. Egger, et al., “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,” PLoS Medicine 4, no. 10 (2007): e296.

[41] H. L. Nguena Nguefack, M. G. Pagé, J. Katz, et al., “Trajectory Modelling Techniques Useful to Epidemiological Research: A Comparative Narrative Review of Approaches,” Clinical Epidemiology 12 (2020): 1205–1222.

[42] I. R. White, P. Royston, and A. M. Wood, “Multiple Imputation Using Chained Equations: Issues and Guidance for Practice,” Statistics in Medicine 30, no. 4 (2011): 377–399.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.